FY2028 Earnings Forecast for AVDL Issued By Leerink Partnrs

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) – Research analysts at Leerink Partnrs lowered their FY2028 earnings per share (EPS) estimates for Avadel Pharmaceuticals in a note issued to investors on Thursday, October 23rd. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of $1.78 per share for the year, down from their previous forecast of $1.80. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ FY2029 earnings at $2.68 EPS.

Avadel Pharmaceuticals (NASDAQ:AVDL) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.08. The company had revenue of $68.13 million during the quarter, compared to analysts’ expectations of $60.28 million. Avadel Pharmaceuticals had a negative return on equity of 3.73% and a negative net margin of 1.32%.Avadel Pharmaceuticals’s revenue for the quarter was up 64.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.14) earnings per share. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS.

Other analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Avadel Pharmaceuticals in a research report on Wednesday, October 8th. Lifesci Capital lowered Avadel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Leerink Partners reissued a “market perform” rating and set a $18.50 price target on shares of Avadel Pharmaceuticals in a report on Thursday, October 23rd. UBS Group lowered Avadel Pharmaceuticals to a “neutral” rating in a report on Tuesday. Finally, Wells Fargo & Company raised Avadel Pharmaceuticals to a “hold” rating in a report on Wednesday, September 3rd. Two investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $18.72.

Avadel Pharmaceuticals Stock Performance

Avadel Pharmaceuticals stock opened at $18.59 on Monday. The stock has a market cap of $1.81 billion, a PE ratio of -619.67 and a beta of 1.46. Avadel Pharmaceuticals has a one year low of $6.38 and a one year high of $18.65. The stock has a fifty day moving average of $15.51 and a 200 day moving average of $11.80.

Hedge Funds Weigh In On Avadel Pharmaceuticals

A number of hedge funds have recently made changes to their positions in AVDL. Investors Asset Management of Georgia Inc. GA ADV boosted its stake in shares of Avadel Pharmaceuticals by 16.4% in the first quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 139,975 shares of the company’s stock worth $1,096,000 after acquiring an additional 19,700 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Avadel Pharmaceuticals by 4.0% in the first quarter. Bank of New York Mellon Corp now owns 234,120 shares of the company’s stock worth $1,833,000 after acquiring an additional 9,025 shares during the period. Pekin Hardy Strauss Inc. bought a new position in Avadel Pharmaceuticals during the first quarter valued at approximately $110,000. Iridian Asset Management LLC CT boosted its stake in Avadel Pharmaceuticals by 47.2% during the first quarter. Iridian Asset Management LLC CT now owns 249,586 shares of the company’s stock valued at $1,954,000 after buying an additional 80,000 shares during the last quarter. Finally, Kovack Advisors Inc. bought a new position in Avadel Pharmaceuticals during the first quarter valued at approximately $90,000. Institutional investors own 69.19% of the company’s stock.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.